Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Revolution Medicines, Inc.. A complete text table follows the diagram.
Revolution Medicines has no product revenue yet; its economic story is the concentrated deployment of capital into drug candidates aimed at one of cancer's hardest targets.
Swipe to explore
The Sankey is a reported R&D portfolio-allocation view for a pre-commercial biotechnology company, not a revenue or profit flow. Every displayed amount is a reported quarterly R&D expense category.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Daraxonrasib (RMC-6236) | 1 | $114M | RAS(ON) multi-selective inhibitor |
| Zoldonrasib (RMC-9805) | 1 | $52.1M | RAS G12D-selective inhibitor |
| Elironrasib (RMC-6291) | 1 | $15M | RAS G12C-selective program |
| RMC-5127 | 1 | $3.4M | Earlier clinical program |
| RAS companion inhibitors | 1 | $0 | Combination-program work |
| Preclinical programs | 1 | $24.1M | Next wave of RAS candidates |
| R&D salaries and benefits | 1 | $61.5M | Scientific and clinical workforce |
| R&D stock compensation | 1 | $44.6M | Equity-based talent cost |
| Other R&D costs | 1 | $29.1M | Facilities and supporting research |
| Total R&D investment | 2 | $344M | 76% of operating expense |
| From | To | Value |
|---|---|---|
| Daraxonrasib (RMC-6236) | Total R&D investment | $114M |
| Zoldonrasib (RMC-9805) | Total R&D investment | $52.1M |
| Elironrasib (RMC-6291) | Total R&D investment | $15M |
| RMC-5127 | Total R&D investment | $3.4M |
| RAS companion inhibitors | Total R&D investment | $0 |
| Preclinical programs | Total R&D investment | $24.1M |
| R&D salaries and benefits | Total R&D investment | $61.5M |
| R&D stock compensation | Total R&D investment | $44.6M |
| Other R&D costs | Total R&D investment | $29.1M |